A nationwide recall of a specific lot of Xanax XR has raised questions for patients using the medication for anxiety and panic disorders.
The FDA’s Enforcement Report shows that Viatris, Inc. voluntarily recalled one lot of alprazolam extended‑release tablets (Xanax XR). The recall, initiated March 17, covers 3‑milligram tablets in 60‑tablet bottles, lot number 8177156, with an expiration date of February 28, 2027. The tablets were manufactured in Ireland and distributed in the U.S. by Viatris Specialty LLC in Morgantown, West Virginia.
Quality control testing found the lot failed to meet FDA dissolution specifications. Dissolution testing measures how quickly and completely the active ingredient is released from a tablet; for extended‑release formulations like Xanax XR, proper dissolution is essential to provide gradual, sustained symptom control. If a tablet does not dissolve correctly, the body may not absorb the intended amount of medication, potentially reducing effectiveness in treating anxiety or panic symptoms.
The FDA classified this as a Class II recall, meaning use of the medication could cause temporary or medically reversible adverse health consequences, but poses little risk of serious adverse health outcomes. Experts note failed dissolution is a quality issue rather than a safety hazard: the drug itself is not expected to cause harm, but it may not work as intended.
Clinicians advise patients not to stop taking Xanax abruptly, because the medication requires a gradual taper to avoid withdrawal symptoms. If you have pills from the affected lot (8177156), continue taking them as directed and contact your prescriber promptly to arrange a replacement prescription or discuss alternatives. Also contact Viatris or consult the FDA recall information for updates. As of April 8, 2026, no FDA press release has been issued and the recall is ongoing.
